Compare F.N.B. Corporation Common Stock (FNB) vs Kenvue Inc. Common Stock (KVUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F.N.B. Corporation Common Stock vs Kenvue Inc. Common Stock — how do they compare? F.N.B. Corporation Common Stock trades at $16.91 (market cap $6.07B), while Kenvue Inc. Common Stock trades at $18.08 (market cap $34.11B). The key difference: Kenvue Inc. Common Stock is far larger — about 5.6× F.N.B. Corporation Common Stock's market cap, and Kenvue Inc. Common Stock pays the higher dividend (4.73%). Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and Kenvue Inc. Common Stock for 1 Days on average.
| FNB | KVUE | |
|---|---|---|
Market Cap | $6.07B | $34.11B |
Volume | 5,600,609 | 27,388,811 |
Sector | Financials | Consumer Staples |
52-Week High | $19.49 | $19.83 |
52-Week Low | $14.65 | $14.11 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $10.61B | $41.62B |
Dividend Yield | 3.05% | 4.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.
The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.
Kenvue (KVUE) trades at $17.76, down 0.39% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $15.12B in 2025, with a net income margin of 10.76% and a P/E ratio of 20.89. Recent news highlights conditional EU approval for Kimberly-Clark's $40B acquisition of Kenvue, potentially impacting future operations and shareholder returns.
The outlook is mixed, with strong profitability and consistent dividend payments offering stability, but the pending acquisition introduces uncertainty. Risks include integration challenges and market volatility. Analyst consensus is a Hold with a $19.50 price target, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About F.N.B. Corporation Common Stock
F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.
Read more on FNB →About Kenvue Inc. Common Stock
Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →
